Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 Jan-Dec:25:1076029618821190.
doi: 10.1177/1076029618821190.

Pharmacomechanical Thrombectomy Versus Catheter-Directed Thrombolysis for Iliofemoral Deep Vein Thrombosis: A Meta-Analysis of Clinical Trials

Tao Tang  1 , Linyi Chen  2 , Jinhui Chen  1 , Tong Mei  1 , Yongming Lu  1
Affiliations
Meta-Analysis

Pharmacomechanical Thrombectomy Versus Catheter-Directed Thrombolysis for Iliofemoral Deep Vein Thrombosis: A Meta-Analysis of Clinical Trials

Tao Tang et al. Clin Appl Thromb Hemost. 2019 Jan-Dec.

Abstract

Early catheter-directed thrombolysis (CDT) for deep vein thrombosis (DVT) can reduce postthrombotic morbidity. Pharmacomechanical thrombolysis (PMT) is a new therapy that can be selected for the treatment of iliofemoral deep vein thrombosis (IFDVT). We performed a meta-analysis of clinical trials comparing PMT versus CDT for treatment of acute IFDVT. Literature on this topic published between January 1, 1990, and June 1, 2018, was identified using PubMed, Embase, Cochrane Library, and Web of Science. Six trials were included in the meta-analysis. Compared to CDT, PMT significantly reduced the Villalta score ( P = .007; I2 = 0%), thrombus score ( P = .01; I2 = 0%), the duration in the hospital ( P = .03; I2 = 64%), and thrombolysis time ( P < .00001, I2 = 0%). There was no significant difference in valvular incompetence events ( P = .21; I2 = 0%), minor bleeding events ( P = .59; I2 = 0%), stent events ( P = .09; I2 = 24%), and clot reduction grade I events ( P = .16; I2 = 43%) between PMT and CDT. Subgroup analysis was performed by dividing the clot reduction grade I events group into PMT plus CDT versus CDT group and significant differences were found ( P = .03, I2 = 0%) as well as for PMT alone versus CDT group ( P = .88, I2 = 37%). This meta-analysis shows that PMT reduces the severity of postthrombotic syndrome (PTS), thrombus score, duration in hospital, and thrombolysis time compared to CDT. More specifically, PMT plus CDT reduces clot reduction grade I events. No significant difference in valvular incompetence events, stent events, and minor bleeding events were found when PMT was compared to CDT.

Keywords: catheter-directed thrombolysis; iliofemoral deep vein thrombosis; pharmacomechanical thrombectomy.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Flow diagram of literature review.
Figure 2.
Figure 2.
Meta-analysis of primary outcomes of clinical trials (Villata score P = .007, I 2 = 0%, thrombus score P = .01, I 2 = 0%, valvular incompetence events P = .21, I 2 = 0%).
Figure 3.
Figure 3.
Meta-analysis of primary outcomes of clot reduction grade I events on primary outcomes with subgroup analysis. (total P = .16, I 2 = 43%), PMT alone versus CDT group (P = .88, I 2 = 37%), and PMT + CDT versus CDT group (P = .03, I 2 = 0%). CDT indicates catheter-directed thrombolysis; M-H, Mantel-Haenszel (a stratification analysis method); PMT, pharmacomechanical thrombolysis.
Figure 4.
Figure 4.
Meta-analysis of secondary outcomes of clinical trials (stent events P = .09, I 2 = 24%; minor bleeding events P = .59, I 2 = 0%, duration of hospital stay P = .03, I 2 = 64%, and thrombolysis time P < .00001, I 2 = 0%).
See this image and copyright information in PMC

References

    1. Kahn SR, Shbaklo H, Lamping DL, et al. Determinants of health-related quality of life during the 2 years following deep vein thrombosis. J Thromb Haemost. 2008;6(7):1105–1112. - PubMed
    1. Comerota AJ, Grewal N, Martinez JT, et al. Postthrombotic morbidity correlates with residual thrombus following catheter-directed thrombolysis for iliofemoral deep vein thrombosis. J Vasc Surg. 2012;55(3):768–773. - PubMed
    1. Bashir R, Zack CJ, Zhao H, Comerota AJ, Bove AA. Comparative outcomes of catheter-directed thrombolysis plus anticoagulation vs anticoagulation alone to treat lower-extremity proximal deep vein thrombosis. JAMA Intern Med. 2014;174(9):1494–1501. - PubMed
    1. Yuksel A, Tuydes O. Midterm outcomes of pharmacomechanical thrombectomy in the treatment of lower extremity deep vein thrombosis with a rotational thrombectomy device. Vasc Endovascular Surg. 2017;51(5):301–306. - PubMed
    1. Kim HS, Patra A, Paxton BE, Khan J, Streiff MB. Adjunctive percutaneous mechanical thrombectomy for lower-extremity deep vein thrombosis: clinical and economic outcomes. J Vasc Interv Radiol. 2006;17(7):1099–1104. - PubMed

Publication types